Release Date: April 2010

GlobalData, the industry analysis specialist’s new report, “Periodontal disease– Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global periodontal disease market. The report identifies the key trends shaping and driving the global periodontal disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global periodontal disease sector. The global periodontal disease market was valued at $1,248m in 2009 and is characterized by efficacious dental procedures such as scaling, root planing and surgery. The periodontal therapeutics market comprises Local Applied Antibodies (LAAs) and systemic applied antibodies. The influx of new drugs and the increase in the uptake of LAAs will the drive the market in the forecast period. The various phases of the developmental pipeline contain 19 molecules. Of these, only five are in Phase III and the rest are in the early stages of development. The pipeline consists of no new antibiotics. The combinations of the tetracylines are expected to improve the efficacy of the treatment. However, the drug is similar in nature to doxycyclines. The entry of cost effective drugs in the forecast period is expected to aid the market growth. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.;